



Biotech Daily

Tuesday October 9, 2018

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ACTINOGEN UP 4%; REVA DOWN 11%**
- * **VISIONEERING: MEDILENS NORDIC 1st NATURALVUE EURO DISTRIBUTOR**
- * **PROBIOTEC COMPLETES \$13.5m BRANDED PRODUCTS SALE TO INOVA**
- * **PHYLOGICA RECEIVES \$2.9m FEDERAL R&D TAX INCENTIVE**
- * **RESAPP REQUESTS 'SLEEP APNOEA TRIAL' TRADING HALT**
- * **MGC REQUESTS 'TGA APPLICATION DEAL' TRADING HALT**
- * **NZ HARBOUR ASSET MANAGEMENT TAKES 5% OF VOLPARA**
- * **INVESTORS MUTUAL REDUCES TO 6% OF MAYNE PHARMA**
- * **CRESO TO RELEASE 23m ESCROW SHARES; MARIJUANA BEER LAUNCH**
- * **NANOSONICS 54k CEO MICHAEL KAVANAGH RIGHTS, 287k OPTIONS AGM**
- * **CELLMID AGM FOR 630k DIRECTOR SHARES, 33% POOL HIKE**
- * **ESENSE PLACEMENT, SHARE CAPITAL EGM**
- * **NUHEARA: EX MICROSOFT, DOPPLER EXEC BRIAN HALL ADVISOR**

MARKET REPORT

The Australian stock market fell 0.97 percent on Tuesday October 9, 2018 with the ASX200 down 59.2 points to 6,041.1 points. Nine of the Biotech Daily Top 40 stocks were up, 25 fell, three traded unchanged and three were untraded. All three Big Caps fell.

Actinogen was the best, up 0.2 cents or 4.2 percent to five cents with 10,000 shares traded. Pharmaxis climbed 3.3 percent; Dimerix, Neuren and Orthocell rose more than two percent; Cyclopharm, Osprey and Prescient were up more than one percent; with Opthea up 0.8 percent.

Reva led the falls, down three cents or 10.7 percent to 25 cents, with 40,418 shares traded. Clinuvel lost 10.1 percent; Paradigm fell 8.1 percent; Avita was down 7.7 percent; Immutep shed 6.1 percent; Cochlear, Ellex, Medical Developments and Nanosonics were down more than five percent; CSL and Imugene fell more than four percent; Factor, Genetic Signatures, Telix and Uscom were down more than three percent; Airxpanders, Bionomics, Impedimed, ITL, Mesoblast, Resmed, Starpharma and Universal Biosensors shed two percent or more; Compumedics and Pro Medicus were down more than one percent; with Cynata and Volpara down by less than one percent.

[VISIONEERING TECHNOLOGIES](#)

Visioneering says it has appointed the Helsingborg, Sweden-based Medilens Nordic AB as the first Europe distributor of its Naturalvue (etafilcon A) one-day contact lenses. Visioneering said Medilens operated in Sweden, Norway, Denmark, Finland and Iceland. Medilens Nordic managing-director Kent Maack said that Visioneering's "revolutionary Naturalvue one-day contact lenses are taking us to the leading edge of vision technology". Visioneering was unchanged at 16.5 cents.

[PROBIOTEC](#)

Probiotec says the Singapore-based Inova Pharmaceuticals has paid \$13.5 million in cash for its Gold Cross, David Craig and Skin Basics brands.

In August, Probiotec said the deal included all associated intellectual property and assets (BD: Aug 24, 2018).

Probiotec was up three cents or 1.95 percent to \$1.57.

[PHYLOGICA](#)

Phylogica says it has received \$2,904,120 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Phylogica said that the rebate related to research and development expenditure for the year to June 30, 2018.

The company said the funds would be used "to accelerate [its] path towards first-in-human trials of its cell penetrating peptides".

Phylogica fell 0.1 cents or 3.1 percent to 3.1 cents.

[RESAPP](#)

Resapp has requested a trading halt "pending the release of an announcement regarding its sleep apnoea clinical study".

Trading will resume on October 11, 2018 or on an earlier announcement.

Resapp last traded at 22 cents.

[MGC \(MEDICAL GRADE CANNABIS\) PHARMACEUTICALS](#)

MGC has requested a trading halt pending an announcement regarding its Australian Therapeutic Goods Administration "authorized prescriber application for use of Cannepil".

Trading will resume on October 11, 2018 or on an earlier announcement.

MGC last traded at 5.1 cents.

[VOLPARA HEATH TECHNOLOGIES](#)

The Wellington, New Zealand-based Harbour Asset Management says it has become a substantial shareholder in Volpara with 9,271,332 shares or 5.174 percent.

Harbour said that between August 3 and October 6, 2018 it acquired 899,000 shares for \$1,010,431 or an average price of \$1.12 a share.

The Harbour substantial shareholder notice said that the shares were held by TEA Custody, Citibank Nominees JP Morgan Nominees, BNP Paribas Nominees and HSBC Nominees.

Volpara fell half a cent or 0.4 percent to \$1.21.

MAYNE PHARMA

Investors Mutual says it has further reduced its substantial holding in Mayne from 115,348,827 shares (7.34%) to 95,169,714 shares (6.05%).

In September, the Sydney-based Investors Mutual said it reduced its holding in Mayne from 129,178,674 shares (8.47%) to 115,348,827 shares (7.34%) (BD: Sep 3, 2018).

Today, the company said it primarily sold shares between September 5 and October 8, 2018, with the single largest sale on October 4 of 2,080,000 shares for \$2,734,368 or \$1.315 a share.

Investors mutual said that registered holders included Sandhurst Trustees, Citicorp Nominees, JP Morgan State Super, State Street and RBC Global Services Australia. Mayne fell 4.5 cents or 3.6 percent to \$1.215 with 12.1 million shares traded.

CRESO PHARMA

Creso says that 23,200,001 shares will be released from ASX escrow on October 20, 2018.

Creso said that, pending vesting conditions, 5,000,000 performance rights would be released from escrow at the same time, along with 2,750,000 unlisted options.

The company said that about 80 percent of the securities were held by directors.

According to the company's most recent Appendix 3B new issue statement, following the release it would have 115,725,544 shares available for trading, with no more shares held in escrow.

In a separate announcement, Creso said that joint venture CLV Frontier Brands launched its marijuana-infused beer in London last week (BD: Jun 25, 2018).

Creso fell 1.5 cents or 2.75 percent to 53 cents.

NANOSONICS

Nanosonics will vote to issue chief executive officer Michael Kavanagh 33,003 short-term incentive performance rights, with 20,900 long-term incentive rights and 286,885 options. Nanosonics said the short-term incentive rights would vest in two equal tranches on August 31, 2019 and 2020, "subject to a service condition" namely remaining employes as the company's chief executive officer.

The company said the long-term incentive rights would vest on September 30, 2021, pending a profit-before-tax "gate" that the average of the coming three years is higher than the profit-before-tax for the year to June 30, 2018.

Nanosonics said that half of the rights would vest on reaching a compound annual growth rate for total shareholder return (CAGR TSR) of 10 percent with the balance rising from 50 percent to 100 percent on a CAGR TSR of 20 percent or more, with the options exercisable at \$3.442 each by September 30, 2024.

Previous rights issues to Mr Kavanagh passed easily in 2016 and with up to 10.3 percent in 2017 (BD: Nov 3, 2017).

The company's notice of meeting said shareholders would vote on the remuneration report and the re-election of directors Steven Sargent and Marie McDonald.

The meeting will be held in the Thomas Keneally Room, Sydney Harbour Marriott, 30 Pitt Street, Sydney on November 9, 2018 at 11am (AEDT).

Nanosonics fell 18 cents or 5.1 percent to \$3.37 with 1.3 million shares traded.

CELLMID

Cellmid will vote to grant 500,000 incentive shares to chief executive officer Maria Halsz, 130,000 shares to director Dennis Eck and increase the fee pool 33 percent to \$400,000. Cellmid said the annual general meeting would also consider the remuneration report and the re-election of chairman Dr David King.

The company said it had decided that a bonus of \$185,000 was appropriate for having achieved the 2017-'18 milestone and Ms Halasz "agreed to receive the bonus in ... shares" with 50 percent to be held in voluntary escrow for two years from issue.

The company said Mr Eck's shares were "in lieu of a cash payment" for his director's fees. The meeting will be held at Automic Group, Level 5, 126 Phillip Street, Sydney, on November 8, 2018 at 11am (AEDT).

Cellmid was up half a cent or 1.3 percent to 38.5 cents.

ESENSE-LAB

Esense says an extraordinary general meeting will vote to approve a placement for about \$4 million and amend the articles of association.

Esense said that shareholders would vote to issue of up to 125,000,000 Chess depository instruments (CDIs) at 80 percent or more of the five-day volume-weighted average price to the date of the placement and 41,666,667 options exercisable at a 100 percent premium to the placement price within four years.

The company said the meeting would vote to issue 300,000 CDIs to Perth's Otsana Capital and 10,000,000 options to Sydney's Everblu Capital, exercisable at a 100 percent premium to placement price.

Esense said two more resolutions were to increase its share capital by a further 2,000,000 New Israeli Shekels (NIS) (\$A776,050) as 200,000,000 shares with a nominal value of 1.0 agora (0.39 Australian cents) each and to amend the articles of association so the share capital was NIS4,000,000 as 400,000,000 shares at a nominal value 1.0 agora each.

The most recent Esense Appendix 3B new issue announcement said it had issued 80,676,813 CDIs with 36,277,999 CDIs quoted on the ASX.

The meeting will be held at 3 Pinchas Sapir Street, Ness Ziona, Israel on November 12, 2018 at 10am Israel time (6pm AEDT).

Esense was unchanged at 3.5 cents.

NUHEARA

Nuheara says it has appointed former Microsoft executive and Doppler Labs chief executive officer Brian Hall to its advisory board.

Nuheara said that the Seattle, Washington-based Mr Hall had extensive experience in running multi-billion hardware businesses at Microsoft for more than 20 years and was formerly Doppler Labs chief executive officer.

The company said that Doppler Labs was "a leader in the wireless earbud market in the US, gaining significant funding and press coverage ... [and] helped lobby for the successful US legislative Over-The-Counter Hearing Aid Act of 2017".

Nuheara was up 0.1 cents or 1.2 percent to 8.5 cents with 2.3 million shares traded.